Enthusiasm For US Biosimilars Wanes For Some, But Not Others
Executive Summary
Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.
You may also be interested in...
US Biosimilar Market – Who's In It For The Long Haul?
A biopharma conference in Mumbai hears how the US biosimilars landscape could potentially change over the long term when deep price cuts set in and payers have a greater say in matters. Might big pharma consider pulling out?
Should Biosimilars Be Cheap? Sponsors Aren't So Sure
Policymakers often frame the value of biosimilars in terms of how inexpensive they are, but sponsors use arguments that resemble those of their innovator counterparts.
Should Biosimilars Be Cheap? Sponsors Aren't So Sure
Policymakers often frame the value of biosimilars in terms of how inexpensive they are, but sponsors use arguments that resemble those of their innovator counterparts.